Twelve-month analysis of real-world evidence from a telehealth obesity-treatment provider using antiobesity medications.

Jamy D Ard, Young-Rock Hong, Gary D Foster, Adam Medcalf, Spencer Nadolsky, Michelle I Cardel
{"title":"Twelve-month analysis of real-world evidence from a telehealth obesity-treatment provider using antiobesity medications.","authors":"Jamy D Ard, Young-Rock Hong, Gary D Foster, Adam Medcalf, Spencer Nadolsky, Michelle I Cardel","doi":"10.1002/oby.24169","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to describe weight changes in members of a large-scale telehealth obesity-treatment provider who were using antiobesity medications (AOMs).</p><p><strong>Methods: </strong>This retrospective observational study analyzed real-world data from adults who initiated AOM treatment with the WW International, Inc. (formerly Weight Watchers) Clinic telehealth program between January 2022 and July 2023 (n = 53,590). The main outcomes were changes in body weight over 12 months, side effects over follow-up, and medication usage patterns.</p><p><strong>Results: </strong>The 53,590 patients who initiated treatment were predominantly female (88.6%), with a mean BMI of 36.9 kg/m<sup>2</sup>. Mean (SD) treatment duration was 5.3 (4.3) months. Program retention rates based on the number of patients whose time from enrollment was at least 3, 6, 9, and 12 months were 78% (n = 39,907/51,247), 63% (n = 25,515/40,203), 58% (n = 15,472/26,794), and 77% (n = 6459/8394), respectively. Average weight loss was 8.9% at 3 months (n = 37,565), 14.1% at 6 months (n = 24,140), 17.7% at 9 months (n = 15,169), and 19.4% at 12 months (n = 6089). Glucagon-like peptide-1 receptor agonist (GLP-1-RA)-based treatments were predominant. Side effects were consistent with the classes of medications used, and frequency declined over time.</p><p><strong>Conclusions: </strong>This real-world analysis of a telehealth-delivered obesity-treatment program demonstrated outcomes consistent with recent phase 3 clinical trials of AOMs, suggesting generalizability beyond clinical trial and in-person settings.</p>","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity (Silver Spring, Md.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/oby.24169","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The objective of this study was to describe weight changes in members of a large-scale telehealth obesity-treatment provider who were using antiobesity medications (AOMs).

Methods: This retrospective observational study analyzed real-world data from adults who initiated AOM treatment with the WW International, Inc. (formerly Weight Watchers) Clinic telehealth program between January 2022 and July 2023 (n = 53,590). The main outcomes were changes in body weight over 12 months, side effects over follow-up, and medication usage patterns.

Results: The 53,590 patients who initiated treatment were predominantly female (88.6%), with a mean BMI of 36.9 kg/m2. Mean (SD) treatment duration was 5.3 (4.3) months. Program retention rates based on the number of patients whose time from enrollment was at least 3, 6, 9, and 12 months were 78% (n = 39,907/51,247), 63% (n = 25,515/40,203), 58% (n = 15,472/26,794), and 77% (n = 6459/8394), respectively. Average weight loss was 8.9% at 3 months (n = 37,565), 14.1% at 6 months (n = 24,140), 17.7% at 9 months (n = 15,169), and 19.4% at 12 months (n = 6089). Glucagon-like peptide-1 receptor agonist (GLP-1-RA)-based treatments were predominant. Side effects were consistent with the classes of medications used, and frequency declined over time.

Conclusions: This real-world analysis of a telehealth-delivered obesity-treatment program demonstrated outcomes consistent with recent phase 3 clinical trials of AOMs, suggesting generalizability beyond clinical trial and in-person settings.

对远程保健肥胖症治疗提供商使用抗肥胖症药物进行为期 12 个月的实际证据分析。
研究目的本研究旨在描述大规模远程保健肥胖症治疗机构中使用抗肥胖药物(AOMs)的成员的体重变化情况:这项回顾性观察研究分析了2022年1月至2023年7月期间开始接受WW国际公司(前身为Weight Watchers)诊所远程医疗项目AOM治疗的成年人(n = 53,590)的真实世界数据。主要结果是12个月内体重的变化、随访期间的副作用以及药物使用模式:开始治疗的 53,590 名患者主要为女性(88.6%),平均体重指数为 36.9 kg/m2。平均(标清)治疗时间为 5.3(4.3)个月。根据入组时间至少为 3 个月、6 个月、9 个月和 12 个月的患者人数计算,项目保留率分别为 78%(n = 39,907/51,247 人)、63%(n = 25,515/40,203 人)、58%(n = 15,472/26,794 人)和 77%(n = 6459/8394 人)。3 个月时的平均体重减轻率为 8.9%(37,565 人),6 个月时的平均体重减轻率为 14.1%(24,140 人),9 个月时的平均体重减轻率为 17.7%(15,169 人),12 个月时的平均体重减轻率为 19.4%(6089 人)。以胰高血糖素样肽-1受体激动剂(GLP-1-RA)为基础的治疗占主导地位。副作用与所使用的药物类别一致,并且随着时间的推移,副作用的发生频率有所下降:这项对远程医疗提供的肥胖症治疗计划进行的真实世界分析表明,其结果与最近进行的AOMs第3期临床试验结果一致,这表明该计划的普遍性超出了临床试验和面对面治疗的范围。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信